101 hits for »HTA «
…Assessment (HTA) and national market structures for access to OMPs. These elements should be fully complementary and integrated. Sadly, gaps still remain. In consequence, EUCOPE wishes to promote a comprehensive view of the system for the development of OMPs. Our vision is bridging the gaps…
…innovation in Europe. We welcome other provisions of the communication including the initiatives on regulatory flexibility and enhancing dialogue and cooperation among regulatory authorities, HTA and national payers. We are also looking forward to seeing more provisions on the EU Health Data Space and other…
…are held by OMP-focused developers. Commenting on the publication of the study, Alexander Natz, EUCOPE Secretary General said: We are at a crossroad. EU institutions, Member States, HTA bodies, payers, pharmaceutical industry and the scientific and rare disease community all share a responsibility to build…
…& reimbursement of ATMPs in the EU – challenges and political implications The Pricing and Reimbursement perspective Pricing & HTA challenges for ATMPs – Case study on CAR-T cells Speakers will include Alexander Natz, EUCOPE Secretary General and other experts representatives of pharmaceutical companies and…
EUCOPE, together with experts from Ministries, HTA agencies and pharmaceutical companies, will take part in the next FORUM Event in Berlin on 9 July 2020. The seminar will give the opportunity to discuss, inter alia, the priorities of the German Presidency of the EU on…
…our take on HTA and evidential options Funding solutions Patient access and cross-border healthcare This paper is the first step of a greater work and reflection from EUCOPE on how our health systems in Europe can embrace these technologies, seen by many as real game-changers…
…agencies relations tasks as well as office management activities, in particular Building and preserving trusted relationships with our members; Addressing members’ needs quickly and effectively; Handling external agencies relations, e.g. with the European Medicines Agency and Member States’ regulatory, HTA and Pricing & Reimbursement bodies…
…and reimbursement matters at Member States’ level. Your ad hoc expertise on national market access issues, as well your close relationship with many national medicines and HTA agencies in Europe, are particularly useful for us, and I’m sure for many of the other members. What…
The Bulgarian Association for Drug Information (BADI) will host its annual conference on “Revolution in Regulatory Affairs – How the pandemic is shaping the regulatory field and sciеnce.” EUCOPE’s Alexander Natz will speak at the 14:45 session “The Implications Of The New EU HTA Regulation…
…market access & cross-functional capabilities to maximise effectiveness in larger or smaller companies 3. Appreciate how to best leverage evidence to demonstrate value to key payers and HTAs EUCOPE’s Alexander Natz will present on “The future EU HTA for medical devices” on 28 June 2022….
You are currently viewing a placeholder content from Facebook. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Instagram. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from X. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information